Open Label Continuation Study in Moderate to Severe Psori... | NCT00626002 | Trialant

Open Label Continuation Study in Moderate to Severe Psori... | NCT00626002 | Trialant

Arms/Interventions Module

Outcomes Module

Primary Outcomes

Measure	Description	Time Frame
Proportion of subjects achieving PGA "clear" (0) or "minimal" (1) scores by visit.		Visit (12 weeks)
Proportion of subjects achieving a > PASI 50 clinical response that is defined as a reduction on PASI scores by at least 50% relative to Baseline, by visit.		Visit (12 weeks)
Proportion of subjects achieving a > PASI 75 clinical response that is defined as a reduction on PASI scores by at least 50% relative to Baseline, by visit.		Visit (12 weeks)
AEs, serious adverse events (SAEs), laboratory data, ADA and vital signs will be assessed throughout the study		Visit (12 weeks)

Contacts/Locations Module